Hydrafinil (9-Fluorenol) powder is an alcohol derivative of fluorene. In the most significant isomer, fluoren-9-ol or 9-hydroxyfluorene, the hydroxy group is located on the bridging carbon between the two benzene rings. Hydrafinil (9-Fluorenol) can be converted to fluorenone by oxidation. It is a white-cream colored solid at room temperature.
|Name||Hydrafinil (9-Fluorenol) powder|
|Chemical name||hydrafinil;Hydranafil;9-FLUORENOL;fluoren-9-ol;Hydroxyfluoren;9h-fluoren-9-ol;Fluoren-9-ol 97%;9-HYDROXYFLUORENE;9-HYDROXY-FLUOREN;9-Fluorenol, 98+%|
|Molecular Weight||182.22 g/mol|
|Melting Point||152-155 °C|
|Half Life||6 to 8 hours|
|Solubility||Chloroform (Slightly), Methanol (Slightly)|
|Application||Used in medicine, health products, food, beverage, cosmetics, biological and chemical reagents and other industries.|
Hydrafinil (9-Fluorenol) powder is an alcohol derivative of fluorene. In the most significant isomer, fluoren-9-ol or 9-hydroxyfluorene, the hydroxy group is located on the bridging carbon between the two benzene rings. Hydroxy fluorene can be converted to Hydrafinil (9-Fluorenol) by oxidation. It is a white-cream colored solid at room temperature.
Hydrafinil (9-Fluorenol) powder is an alcohol derivative of fluorene and is being clasisfied as a eugeroic compound, promoting wakefulness. The company Cephalon investigated Hydrafinil (9-Fluorenol) in comparison to the popular eugeroic drug modafinil. In their comparison research with rodents, they noted that Hydrafinil (9-Fluorenol) was significantly more effective than modafinil (up to 39%). Although it has dopamine reuptake properties, they tend to be pretty weak.
Hydrafinil (9-Fluorenol) powder is an unregulated research chemical originally synthesized by Cephalon Pharmaceuticals (now owned by Teva) as a eugeroic (wakefulness-promoting agent). After its synthesis, Hydrafinil (9-Fluorenol) was one of several agents to be considered as a hypothetical successor to the popularized and FDA-approved drug, Provigil (Modafinil). Comparative data from animal trials indicated that Hydrafinil (9-Fluorenol) exhibited ~39% greater eugeroic efficacy than modafinil over a short-term (4 hour) span.
However, for undisclosed reasons, Cephalon scrapped development of Hydrafinil (9-Fluorenol) as a potentially novel eugeroic. Instead, they directed efforts and resources to investigate, develop, and market the drug armodafinil. Armodafinil (sold under the brand name “Nuvigil”) would become known as the official pharmaceutical successor to Provigil, leaving many to wonder whether Hydrafinil (9-Fluorenol) may have been a superior development.
Some speculate Hydrafinil (9-Fluorenol)’s former usage as an insecticide in the late 1930s, proven toxicity to aquatic wildlife, and an expiring Cephalon patent may have been reason enough to discontinue its development. As of 2015, Hydrafinil (9-Fluorenol) has regained popularity among nootropic enthusiasts and is now being sold as an unregulated substance online under the brand “Hydrafinil.” Many self-experimenters are vouching for its efficacy, but others are skeptical of these claims and wary of its undocumented, potentially perilous side effect profile.
The mechanism of action associated with hydrafinil is relatively unclear. Many speculate that it functions as a 5-HT6 receptor antagonist and negligible dopamine reuptake inhibitor (DRI). Whether these speculations are accurate is debatable since it hasn’t been formally researched in humans. In any regard, hydrafinil likely bolsters psychomotor vigilance and cognitive performance principally via upregulation of dopaminergic and noradrenergic transmission.
9-Fluorenol is also known as hydrafinil and is the next generation of cognitive stimulants shown to be 39% more effective than modafinil in maintaining alertness. It is 140% as efficacious as modafinil at wakefulness promotion and does not have the same interactions as modafinil. It also does not last as long, making it easier to dose more effectively, without having to wait out 12 hours of effects
Hydrafinil (9-fluorenol) not addictive
Hydrafinil (9-Fluorenol) belongs to a class of drugs known as Eugeroics. These are stimulants that produce long lasting mental arousal leading to wakefulness. The idea behind the production of these drugs is to enhance alertness without necessarily eliciting the peripheral body effects or better yet the abuse/tolerance/ addiction of the customary stimulants. And Hydrafinil (9-Fluorenol) is no different.
Hydrafinil’s stimulation of dopamine pathways is far less substantial than modafinil’s which means that it is less likely to be addictive.
Hydrafinil (9-fluorenol) not carcinogenic and toxic to humans
This drug is an alcohol derivative of fluorine. Its hydroxyl group is placed between its two benzene rings on the bridging carbon. Oxidation process can be used to convert the hydroxyfluorene to fluorenone. This compound is not carcinogenic neither is it toxic to humans. Thus, a study was carried out by Chemists working for Cephalon (a bio-pharmaceutical company), ostensibly to come up with a drug that would succeed Modafinil, the anti-narcolepsy drug.
It also does not last as long, making it easier to dose more effectively, without having to wait out 12 hours of effects. It has slightly lower DAT affinities but had higher eugeroic actions. It is more potent than modafinil with 50-100mg corresponding to 100-200mg for modafinil. It shows no toxicity and no liver interactions.
Hydrafinil (9-Fluorenol) is toxic to aquatic organisms including algae, bacteria, and crustaceans. Hydrafinil (9-Fluorenol) was patented as an insecticide in 1939, and is an algaecide against the green algae Dunaliella bioculata.
Its toxicity and carcinogenicity in humans are unknown.
A study published by chemists working for the biopharmaceutical company Cephalon to develop a successor to the eugeroic modafinil reported that the corresponding Hydrafinil (9-Fluorenol) derivative was 39% more effective than modafinil at keeping mice awake over a 4-hour period. It is a weak dopamine reuptake inhibitor with an IC50 of 9 μM, notably 59% weaker than modafinil (IC50 = 3.70 μM) despite being a stronger eugeroic, potentially making it even less liable for addiction. It also showed no affinity for cytochrome P450 2C19, unlike modafinil.